• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

骨质疏松症。发病率、后果及风险因素。

Osteoporosis. Frequency, consequences, and risk factors.

作者信息

Ross P D

机构信息

Hawaii Osteoporosis Center, Honolulu.

出版信息

Arch Intern Med. 1996 Jul 8;156(13):1399-411. doi: 10.1001/archinte.156.13.1399.

DOI:10.1001/archinte.156.13.1399
PMID:8678708
Abstract

More than half of all women and about one third of men will experience osteoporotic fractures during their lives. Although no symptoms occur prior to fracture, bone mineral density and other risk factors can be used to identify high-risk patients, and because effective interventions exist, many of these fractures are now preventable. The proportion of people who are affected, the mortality and morbidity resulting from osteoporotic fractures, and the major known risk factors are discussed. Greater attention should be given to measuring bone mineral density and identifying other risk factors to quantitate the degree of fracture risk among patients (with or without a history of previous fractures), because the consequences of fractures often are severe, and no symptoms other than fractures are associated with disease progression.

摘要

超过半数的女性和大约三分之一的男性在一生中会发生骨质疏松性骨折。虽然骨折前没有症状,但骨密度和其他风险因素可用于识别高危患者,并且由于存在有效的干预措施,现在许多此类骨折是可以预防的。本文讨论了受影响人群的比例、骨质疏松性骨折导致的死亡率和发病率以及主要的已知风险因素。应更加重视测量骨密度和识别其他风险因素,以量化患者(无论有无既往骨折史)的骨折风险程度,因为骨折的后果往往很严重,而且除了骨折外没有其他症状与疾病进展相关。

相似文献

1
Osteoporosis. Frequency, consequences, and risk factors.骨质疏松症。发病率、后果及风险因素。
Arch Intern Med. 1996 Jul 8;156(13):1399-411. doi: 10.1001/archinte.156.13.1399.
2
Update on the epidemiology of osteoporosis.骨质疏松症流行病学最新情况
Curr Rheumatol Rep. 2000 Feb;2(1):74-86. doi: 10.1007/s11926-996-0072-9.
3
Recent developments in the epidemiology of osteoporosis.
Curr Opin Rheumatol. 2002 Jul;14(4):411-5. doi: 10.1097/00002281-200207000-00014.
4
The worldwide problem of osteoporosis: insights afforded by epidemiology.骨质疏松症的全球问题:流行病学提供的见解
Bone. 1995 Nov;17(5 Suppl):505S-511S. doi: 10.1016/8756-3282(95)00258-4.
5
Incidence of fragility fractures.脆性骨折的发病率。
Aging Clin Exp Res. 2007 Aug;19(4 Suppl):7-11.
6
[Epidemiology of osteoporosis].[骨质疏松症的流行病学]
Schweiz Med Wochenschr. 1997 Apr 19;127(16):659-67.
7
Bone mineral density thresholds for pharmacological intervention to prevent fractures.预防骨折的药物干预的骨密度阈值。
Arch Intern Med. 2004 May 24;164(10):1108-12. doi: 10.1001/archinte.164.10.1108.
8
Epidemiology of spinal osteoporosis.脊柱骨质疏松症的流行病学
Spine (Phila Pa 1976). 1997 Dec 15;22(24 Suppl):2S-11S. doi: 10.1097/00007632-199712151-00002.
9
Epidemiology, etiology, and diagnosis of osteoporosis.骨质疏松症的流行病学、病因学及诊断
Am J Obstet Gynecol. 2006 Feb;194(2 Suppl):S3-11. doi: 10.1016/j.ajog.2005.08.047.
10
Risk factors for a first-incident radiographic vertebral fracture in women > or = 65 years of age: the study of osteoporotic fractures.65岁及以上女性首次发生影像学椎体骨折的危险因素:骨质疏松性骨折研究
J Bone Miner Res. 2005 Jan;20(1):131-40. doi: 10.1359/JBMR.041003. Epub 2004 Oct 11.

引用本文的文献

1
DNA hydroxy methylases Tet1 and Tet2 regulate bone aging and bone marrow stromal cell metabolism through the IGF-1/mTOR signaling axis.DNA羟甲基化酶Tet1和Tet2通过IGF-1/mTOR信号轴调节骨骼衰老和骨髓基质细胞代谢。
Stem Cells. 2025 Jul 21;43(8). doi: 10.1093/stmcls/sxaf026.
2
Effects of metabolic syndrome on bone mineral density in postmenopausal Turkish women.代谢综合征对绝经后土耳其女性骨密度的影响。
Afr Health Sci. 2023 Sep;23(3):99-108. doi: 10.4314/ahs.v23i3.13.
3
Fractures reduction with osteoporotic treatments in patients over 75-year-old: A systematic review and meta-analysis.
75岁以上患者骨质疏松治疗的骨折复位:一项系统评价和荟萃分析。
Front Aging. 2022 Nov 2;3:845886. doi: 10.3389/fragi.2022.845886. eCollection 2022.
4
Pharmacological Therapies for Osteoporosis: A Bayesian Network Meta-Analysis.骨质疏松症的药物治疗:一项贝叶斯网络荟萃分析。
Med Sci Monit. 2022 Apr 17;28:e935491. doi: 10.12659/MSM.935491.
5
Evaluation of knowledge about osteoporosis risk factors among adults above 40 years of age in Hafar Al-Batin Region, Saudi Arabia.沙特阿拉伯哈费尔巴廷地区40岁以上成年人骨质疏松症危险因素知识评估。
J Family Med Prim Care. 2021 Aug;10(8):3089-3093. doi: 10.4103/jfmpc.jfmpc_386_21. Epub 2021 Aug 27.
6
Iron accumulation deteriorated bone loss in estrogen-deficient rats.铁蓄积使去势大鼠的骨丢失恶化。
J Orthop Surg Res. 2021 Aug 24;16(1):525. doi: 10.1186/s13018-021-02663-4.
7
Association between self-reported walking speed and calcaneal stiffness index in postmenopausal Japanese women.绝经后日本女性自述行走速度与跟骨硬度指数的相关性。
BMC Geriatr. 2020 Nov 11;20(1):466. doi: 10.1186/s12877-020-01858-4.
8
The Efficacy of PTH and Abaloparatide to Counteract Immobilization-Induced Osteopenia Is in General Similar.甲状旁腺激素(PTH)和abaloparatide 对抗制动性骨质疏松的疗效总体上相似。
Front Endocrinol (Lausanne). 2020 Oct 9;11:588773. doi: 10.3389/fendo.2020.588773. eCollection 2020.
9
Linear and Non-linear Correlations Between Serum Phosphate Level and Bone Mineral Density in Type 2 Diabetes.血清磷酸盐水平与 2 型糖尿病患者骨密度的线性和非线性相关性。
Front Endocrinol (Lausanne). 2020 Jul 30;11:497. doi: 10.3389/fendo.2020.00497. eCollection 2020.
10
Real-world persistence and adherence with oral bisphosphonates for osteoporosis: a systematic review.真实世界中骨质疏松症患者口服双膦酸盐的持续性和依从性:系统评价。
BMJ Open. 2019 Apr 14;9(4):e027049. doi: 10.1136/bmjopen-2018-027049.